TempraMed Expands Temperature-Controlled Medication Storage Solutions Across Europe and North America
核心洞察
TempraMed Technologies (搜索) has secured strategic distribution partnerships across the Netherlands, Belgium, Luxembourg, Israel, and Turkey, expanding access to its VIVI temperature-controlled medication storage solutions.
The company's patented VIVI product line represents the only non-powered solution proven to protect temperature-sensitive injectable medications from heat and cold exposure without refrigeration or batteries.
TempraMed completed a successful public listing on Canadian and Frankfurt stock exchanges, raising C$7.4 million to accelerate global expansion and address the critical need for medication temperature protection.
TempraMed Technologies (搜索) Ltd. has significantly expanded its global footprint through strategic distribution partnerships across Western Europe and established manufacturing capabilities in North America, positioning the medical technology company to address the critical challenge of temperature-sensitive medication storage for millions of patients worldwide.
The Vancouver-based company announced a distribution partnership with Salomo Executive (搜索), a leading healthcare logistics company in the Netherlands, marking its strategic expansion into Western Europe. This collaboration will make TempraMed's VIVI product portfolio accessible across brick-and-mortar pharmacies, medical distributors, and medical-focused retail channels throughout the Benelux region.
Strategic Market Expansion
Salomo Executive (搜索) brings extensive experience working with major pharmaceutical companies including Merck & Co. (搜索) (MSD) and operates partnerships with leading pharmacy chains comprising over 500 locations, along with numerous independent pharmacies, medical wholesalers, and diabetes (搜索)-focused webshops throughout the Netherlands, Belgium, and Luxembourg.
"We are thrilled to collaborate with Salomo Executive (搜索), whose deep expertise in healthcare logistics and omnichannel distribution aligns perfectly with TempraMed's global growth strategy," said Ron Nagar, CEO of TempraMed. "This partnership marks an important step in our broader expansion across Europe and other key international markets."
The expansion addresses a significant market need, with the Netherlands alone having approximately 1.2 million people living with diabetes (搜索), and an additional 1.3 million people with prediabetes (搜索) according to Maastricht University research. The rising prevalence of diabetes has created critical demand for dependable, temperature-controlled storage for insulin and other injectable medications.
Innovative Technology Platform
TempraMed's patented VIVI technology represents the only non-powered solution currently available that reliably maintains temperature-sensitive medications within safe temperature ranges in real-world conditions. The FDA-registered, space-grade thermal insulation devices work continuously without batteries, refrigeration, or external power sources.
The company's product line includes the VIVI Cap and VIVI EPI devices, designed to protect medications from heat and cold exposure during daily transport, travel, and routine use. In 2025, TempraMed launched the VIVI Cap Smart device, which integrates digital health functionality with established passive temperature-protection technology, enabling real-time tracking of compliance, efficacy, and side effects.
Global Commercial Progress
During 2025, TempraMed established multiple strategic partnerships to expand its commercial distribution network:
- Exclusive distribution partnership with Guri A.A.O in Israel
- Commercial distribution agreement with a leading Turkish healthcare distributor
- Strategic agreement with Maccabi Healthcare Services, Israel's second-largest HMO serving more than 2.8 million members
The company strengthened its scientific foundation by appointing Professor Dr. Lutz Heinemann, a globally recognized leader in diabetes (搜索) research and insulin pharmacology, to its Scientific Advisory Board. TempraMed also expanded its intellectual property portfolio with an additional patent granted in South Korea.
Manufacturing and Capital Expansion
To address forecasted increased demand, TempraMed announced a new manufacturing facility in Florida, designed to increase output, reduce cost of goods sold, and enhance service for business-to-business customers. The company completed a successful public listing in November 2025 on the Canadian Securities Exchange under "VIVI" and the Frankfurt Stock Exchange under "9DY," raising an oversubscribed C$7.4 million.
Addressing Global Healthcare Challenge
Hundreds of millions of people worldwide rely on insulin and other temperature-sensitive injectable medications daily. These drugs often lose potency when exposed to heat or cold outside tightly controlled ranges, particularly during transport and routine use beyond traditional cold-chain environments.
"We are addressing a long-standing global healthcare problem that directly impacts patient safety and outcomes," commented Ilan Cohen, Chairman of TempraMed. "The Company's technology has the potential to redefine how temperature-sensitive medications are protected worldwide, creating meaningful value for patients, healthcare systems and shareholders alike."
Looking ahead to 2026, TempraMed plans to accelerate market penetration across North America, Europe, the Middle East, and Asia through new healthcare, payor, and pharmacy partnerships, while advancing next-generation product development and working toward insurance reimbursement for its product portfolio.